CORVENTIS
"CORVENTIS" is a word mark owned by Atrium Therapeutics, Inc., filed at the EUIPO on October 13, 2026. It is under examination and covers classes 5 and 42.
- Status
- Under examination
- Filed
- October 13, 2026
- Registered
- Not yet
- Priority date
- June 25, 2026
- Claimed from United States
- Application no.
- 019435000
- Registration no.
- Not yet
- Office
- EUIPO
- European Union Intellectual Property Office
- Mark type
- Word mark
- 2 classes
Who owns CORVENTIS
The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.
Owner
Atrium Therapeutics, Inc.
Representative
Zacco Denmark A/S
Zacco Denmark A/S
What the mark covers
The products and services CORVENTIS is filed for, grouped by Nice class.
oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Biological, medicinal and pharmaceutical preparations, namely, oligonucleotide-based therapeutics for the treatment of cardiovascular, cardiomyopathies, and heart muscle related diseases and disorders; Therapeutic pharmaceuticals in the nature of oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of and prevention of musculoskeletal, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, and muscle atrophy related diseases and disorders; pharmaceutical preparations for the treatment and prevention of viral, metabolic, endocrine, musculoskeletal, autoimmune, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, neurodegenerative, gastrointestinal, hormonal, dermatological, psychiatric, genetic, and immune system related diseases and disorders; pharmaceutical preparations for the treatment and prevention of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; therapeutic pharmaceutical for the treatment and prevention of viral, metabolic, endocrine, musculoskeletal, autoimmune, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, neurodegenerative, gastrointestinal, hormonal, dermatological, psychiatric, genetic, and immune system related diseases and disorders; therapeutic pharmaceuticals for the treatment and prevention of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; Chemicals for use in medical laboratories and/or for medical diagnostic purposes; therapeutic and diagnostic preparations and reagents for use in medical laboratories and/or for medical diagnostic purposes; biochemical, biological, biotechnological reagents, preparations and substances for use in medical laboratories and/or for medical diagnostic purposes; vaccine preparations; proteins for use in recombinant DNA technology for use in medical laboratories and/or for medical diagnostic purposes; nucleic acid reagents, agents, preparations and substances for medical purposes; nucleic acid sequences for medical and veterinary use; oligonucleotides for diagnostic purposes; oligonucleotides for medical diagnostic purposes; oligonucleotides for medical use; oligonucleotides for pharmaceutical purposes; pharmaceutical preparations against genetic diseases; pharmaceutical preparations against metabolic diseases; pharmaceutical preparations against neurological diseases; pharmaceutical preparations for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, respiratory diseases, cancer, allergies, gynecological diseases, rheumatic diseases, urological diseases, gastroenterological diseases, infectious diseases, eye disease, dermatological diseases, autoimmune diseases, blood diseases, genital diseases, endocrine diseases, intestinal diseases, internal medicine diseases; pharmaceutical preparations for wound healing; reagents for medical purposes; reagents for use in medical genetic testing; reagents for use in veterinary genetic testing; tumor suppressing agents
Medical and scientific research, namely, conducting clinical trials; providing medical and scientific research information in the fields of pharmaceuticals, biotechnology, and clinical trials; pharmaceutical research and development; pharmaceutical products development; research and development in the field of biotechnology; Providing medical and scientific research information in the fields of pharmaceuticals and biotechnology; Medical and scientific research, namely, conducting clinical trials for others; laboratory research services in the fields of life science, biotechnology and genomics; scientific research services in the fields of life science, biotechnology and genomics; biological, biotechnological, chemical and biochemical research, analysis and development services in the fields of life science, biotechnology and genomics; contract research services in the fields of life science, biotechnology and genomics; nucleic acids discovery, analysis and research and development services; nucleic acids and genomics research and development services for drugs and pharmaceutical discovery and research; consultancy services relating to nucleic acids and genomics; research services for nucleic acids for therapeutic or diagnostic use; genetic research; research and development services in the field of genomics; research and development services relating to vaccines and medicines; research in the field of nucleic acid technology, namely, a proprietary technology platform containing non-viral nanoparticles; scientific analysis services for the identification and physical characterization of chemical molecules; scientific and technical services, namely, scientific analysis of industrial installations; scientific and technological services, namely, applied scientific research and development services, namely, conception of development or commercial batches for third parties in the fields of pharmaceuticals and chemicals; scientific and technological services, namely, consulting and assistance in the research and development of chemicals and pharmaceuticals, including experimental and production processes and installations; scientific and technological services, namely, consulting and assistance in the research and development of pharmaceuticals; scientific development services in the field of biochemistry; scientific laboratory services; scientific research and development services for chemicals for the products of third parties, namely, the scientific and technical development of synthetic processes in the field of chemistry and biochemistry; scientific research and development services in the field of pharmaceuticals; scientific research and scientific and technical development in the field of pharmaceutical, chemical, agrochemical and industrial processes; scientific research services, namely, nucleic acid analysis; scientific research services, namely, oligonucleotide analysis; scientific services, namely, scientific analysis allowing the identification and physical characterization of chemical molecules; scientific services, namely, scientific research and industrial analysis in the field of pharmaceuticals, chemicals, and agrochemical and industrial processes; scientific study and research in the area of industrial quality; development of methods of analysis for chemical and pharmaceutical products and bio-organics; scientific study and research services in the field of industrial safety; design of synthetic DNA, genes and oligonucleotides for others; development services, namely, design of manufacturing processes for others in the field of oligonucleotides; scientific services, namely, providing technical information in the field of pharmaceutical manufacturing
About CORVENTIS
Who owns the trademark "CORVENTIS"?
The EUIPO trademark "CORVENTIS" (application 019435000) is owned by Atrium Therapeutics, Inc.
What is the status of "CORVENTIS"?
Its status at the EUIPO is: under examination.
Get this data via the API
Everything on this page comes from the Signa API. Pull CORVENTIS and marks like it into your own product with one request.
GET/v1/trademarks/{id}The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/eventsEvery step in the office history
GET/v1/proceedings?trademark_id={id}Oppositions and cancellations against the mark
ID=tm_01a1393a-2f7a-7353-93a8-d23eee98c332
curl https://api.signa.so/v1/trademarks/$ID \
-H "Authorization: Bearer $SIGNA_API_KEY"{
"id": "tm_01a1393a-2f7a-7353-93a8-d23eee98c332",
"object": "trademark",
"mark_text": "CORVENTIS",
"status": {
"primary": "pending",
"stage": "examining"
},
"office_code": "EM",
"application_number": "019435000",
"filing_date": "2026-10-13",
"nice_classes": [
5,
42
],
"owners": [
{
"name": "Atrium Therapeutics, Inc.",
"entity_id": "ent_019fbd7c-3edf-73aa-927e-4b9fe705365d"
}
]
}